It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.

ZIEXTENZO can help protect you from the risk of infection

Your doctor prescribed ZIEXTENZO to help reduce the risk of infection during chemotherapy. ZIEXTENZO is a man-made form of granulocyte colony-stimulating factor (G-CSF) called pegfilgrastim. G-CSF is a natural substance produced by the body. The purpose of G-CSF is to stimulate the growth of neutrophils, a type of white blood cell important in the body's fight against infection.

Ziextenzo Logo

ZIEXTENZO is a biosimilar of Neulasta®

Ziextenzo vs Neublasta

Neulasta® and ZIEXTENZO are biologics, which are complex medications developed by cutting-edge technology. Biologics may consist of sugars, proteins, or nucleic acids, or may be living entities such as cells and tissues.

What are biosimilars?

What are biosimilars

*The alternative biologic tbo-filgrastim (Granix®) was treated as a biosimilar for the purposes of the analysis.

References: 1. ZIEXTENZO Prescribing Information. Sandoz Inc. March 2021. 2. US Food and Drug Administration. Biosimilar basics for patients. Accessed June 12, 2023. 3. Nahleh Z, Lyman GH, Schilsky RL, et al. Use of biosimilar medications in oncology. JCO Oncol Pract. 2022;18(3):177-186. 4. US Food and Drug Administration. Biosimilar product information. Accessed June 12, 2023. 5. Socal M, et al. Biosimilar Medications – Savings Opportunities for Large Employers. Published March 2020. Accessed June 14, 2023. 

Granix is a registered trademark of Cephalon, Inc.
Neulasta is a registered trademark of Amgen Inc.